A multicenter international randomized placebo controlled double-blind parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 yea

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    High Risk Tia
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 18 years of age or older
    2. Acute onset of neurological deficit attributed to noncardioembolic focal brain ischemia due to:
      • Non-cardioembolic ischemic stroke and either of the following:

You may not be eligible for this study if the following are true:

    1. Recent ischemic stroke within 7 days before index stroke event
    2. Strokes following procedures (e.g. TAVI, CABG) or strokes due to other rare causes (e.g. bacterial endocarditis, vertebral artery dissections)
    3. Known pre-stroke

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.